Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T61997 | Target Info | |||
Target Name | Core proteasome 20S complex (PS 20S) | ||||
Synonyms |
Proteasome subunit alpha; Proteasome component; PSC; Multicatalytic endopeptidase complex; Macropain; HC
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | PSMA1; PSMA2 | ||||
Biochemical Class | Peptidase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Nuclear factor NF-kappa-B (NFKB) | Successful Target | ||||
UniProt ID | NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN | |||||
Gene Name | NFKB1; NFKB2; RELA; RELB; REL | |||||
Synonyms |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 9.7 nM | [1] | ||
Co-Target Name | Cathepsin G (CTSG) | Clinical trial Target | ||||
UniProt ID | CATG_HUMAN | |||||
Gene Name | CTSG | |||||
Synonyms |
CG
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 520 nM | [2] | ||
Co-Target Name | Proteasome beta-5 (PS beta-5) | Patented-recorded Target | ||||
UniProt ID | PSB5_HUMAN | |||||
Gene Name | PSMB5 | |||||
Synonyms |
Proteasome subunit beta type-5; Proteasome subunit X; Proteasome subunit MB1; Proteasome epsilon chain; Proteasome chain 6; Multicatalytic endopeptidase complex epsilon chain; Macropain epsilon chain; MB1; LMPX
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 0.5 nM | [3] | ||
Co-Target Name | Proteasome beta-9 (PS beta-9) | Patented-recorded Target | ||||
UniProt ID | PSB9_HUMAN | |||||
Gene Name | PSMB9 | |||||
Synonyms |
Really interesting new gene 12 protein; RING12; Proteasome subunit beta-1i; Proteasome subunit beta type-9; Proteasome chain 7; PSMB6i; Multicatalytic endopeptidase complex chain 7; Macropain chain 7; Low molecular mass protein 2; LMP2
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 3 nM | [4] | ||
Co-Target Name | Proteasome beta-8 (PS beta-8) | Patented-recorded Target | ||||
UniProt ID | PSB8_HUMAN | |||||
Gene Name | PSMB8 | |||||
Synonyms |
Y2; Really interesting new gene 10 protein; RING10; Proteasome subunit beta-5i; Proteasome subunit beta type-8; Proteasome component C13; PSMB5i; Multicatalytic endopeptidase complex subunit C13; Macropain subunit C13; Low molecular mass protein 7; LMP7
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 3.3 nM | [5] | ||
Co-Target Name | Proteasome beta-10 (PS beta-10) | Patented-recorded Target | ||||
UniProt ID | PSB10_HUMAN | |||||
Gene Name | PSMB10 | |||||
Synonyms |
Proteasome subunit beta-2i; Proteasome subunit beta type-10; Proteasome MECl-1; Multicatalytic endopeptidase complex subunit MECl-1; Macropain subunit MECl-1; MECL1; Low molecular mass protein 10; LMP10
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 940 nM | [5] | ||
Co-Target Name | Proteasome component C5 (PSMB1) | Co-Target | ||||
UniProt ID | PSB1_HUMAN | |||||
Gene Name | PSMB1 | |||||
Synonyms |
Proteasome subunit beta type-1; Macropain subunit C5; Multicatalytic endopeptidase complex subunit C5; Proteasome gamma chain
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 19 nM | [3] | ||
Co-Target Name | Proteasome subunit beta type-2 (PSMB2) | Co-Target | ||||
UniProt ID | PSB2_HUMAN | |||||
Gene Name | PSMB2 | |||||
Synonyms |
Macropain subunit C7-I; Multicatalytic endopeptidase complex subunit C7-I; Proteasome component C7-I
Click to Show/Hide
|
|||||
Representative Drug(s) | Bortezomib | Drug Info | IC50 = 128 nM | [6] | ||
Co-Target Name | Chymotrypsinogen B (CTRB1) | Co-Target | ||||
UniProt ID | CTRB1_HUMAN | |||||
Gene Name | CTRB1 | |||||
Representative Drug(s) | Bortezomib | Drug Info | Ki = 320 nM | [7] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Optimization of a series of dipeptides with a P3 beta-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome. Medchemcomm. 2012;3:710-9. | ||||
REF 2 | Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008 Feb 28;51(4):1068-72. | ||||
REF 3 | Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death. Eur J Med Chem. 2018 Feb 25;146:636-650. | ||||
REF 4 | Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors. Eur J Med Chem. 2019 Feb 15;164:423-439. | ||||
REF 5 | Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019 Nov 15;182:111646. | ||||
REF 6 | Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles. Eur J Med Chem. 2019 Feb 15;164:602-614. | ||||
REF 7 | Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.